ClinicalTrials.gg

Program

Emtricitabine

Also written as “E/C/F/TAF”, “B/F/TAF” and “F/TAF”.

Its studies are mostly in HIV Infections · Acquired Immunodeficiency Syndrome · Coinfection · Kidney Failure, Chronic · Hepatitis C, led by 5 companies.

Furthest: phase 4, since Mar 23, 200550 company-led studies, 7 open or runningNext primary completion: Jun 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences427 open or runningphase 4since Mar 23, 2005Mar 23, 2005Jun 2027phase 4 · NCT06337032
Triangle Pharmaceuticals30 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
GlaxoSmithKline20 open or runningphase 1since Nov 2, 1999Nov 2, 1999none ahead
Laboratorio Elea Phoenix20 open or runningphase 4since Oct 10, 2017Oct 19, 2015none ahead
The Crofoot Research Center10 open or runningphase 4since May 12, 2020May 12, 2020none ahead

Also a collaborator on its studies: Merck, Johnson & Johnson and Bristol-Myers Squibb.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 36 studies since Nov 2, 1999.

  1. Jan 12, 2018Phase 3 study in HIV-1 InfectionGilead Sciences · NCT03405935 · 86 enrolled · Belgium, France, Italy and more
  2. May 24, 2018Phase 3 study in HIV-1/HBV Co-InfectionGilead Sciences · NCT03547908 · 244 enrolled · United States, China, Dominican Republic and more
  3. Aug 13, 2018Phase 3 study in HIV-1 InfectionGilead Sciences · NCT03631732 · 496 enrolled · United States
  4. Feb 7, 2019Phase 1 study in HIV InfectionsGlaxoSmithKline · NCT03836729 · 16 enrolled · United States
  5. May 21, 2019Phase 1 study in HIV-1-infectionGilead Sciences · NCT03960645 · 62 enrolled · United States, Dominican Republic, Thailand
  6. Oct 28, 2019Phase 2 study in HIV-1-infectionGilead Sciences · NCT04143594 · 183 enrolled · United States, Dominican Republic, Puerto Rico
  7. May 12, 2020The Crofoot Research Center's first study: phase 4 study in Acquired Immunodeficiency SyndromeNew to The Crofoot Research CenterThe Crofoot Research Center · NCT04388904 · 75 enrolled · United States
  8. Aug 2, 2021Phase 3 study in Pre-Exposure Prophylaxis of HIV InfectionGilead Sciences · NCT04994509 · 5,368 enrolled · South Africa, Uganda
  9. Oct 23, 2023Phase 4 study in HIV-1-infectionGilead Sciences · NCT06104306 · 33 enrolled · United States, Canada, France
  10. Mar 22, 2024Phase 4 study in HIV-1-infectionGilead Sciences · NCT06337032 · 350 planned · Argentina, Panama, South Africa and more
  11. Oct 4, 2024Phase 3 study in HIV-1-infectionGilead Sciences · NCT06630286 · 609 enrolled · United States, Argentina, Australia and more
  12. Jun 27, 2025Phase 1 study in HIV-1-infectionGilead Sciences · NCT07055451 · 16 enrolled · United States, South Africa
  13. Jun 8, 2026Phase 2 study in HIV-1-infectionGilead Sciences · NCT07645287 · 175 planned · United States, Australia, Canada and more
  14. Jul 13, 2026Phase 3 study in HIV-1-infectionGilead Sciences · NCT07708727 · 700 planned · United States, Canada, Germany and more

Ahead

  1. Jun 2027Primary completion: phase 4 study in HIV-1-infectionGilead Sciences · NCT06337032
  2. Aug 2027Primary completion: phase 2 study in HIV-1-infectionGilead Sciences · NCT07645287
  3. Mar 2028Primary completion: phase 1 study in HIV-1-infectionGilead Sciences · NCT07055451
  4. Oct 2030Primary completion: phase 3 study in HIV-1-infectionGilead Sciences · NCT07708727

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule

Studies

All 50 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07708727HIV-1-infection · United States, Canada, Germany and more3RecruitingGilead SciencesOct 2030700
NCT07645287HIV-1-infection · United States, Australia, Canada and more2RecruitingGilead SciencesAug 2027175
NCT07055451HIV-1-infection · United States, South Africa1Active, not recruitingGilead SciencesMar 202816
NCT06630286HIV-1-infection · United States, Argentina, Australia and more3Active, not recruitingGilead SciencesApr 17, 2026609
NCT06337032HIV-1-infection · Argentina, Panama, South Africa and more4RecruitingGilead SciencesJun 2027350
NCT06104306HIV-1-infection · United States, Canada, France4CompletedGilead SciencesJan 29, 202533
NCT04994509Pre-Exposure Prophylaxis of HIV Infection · South Africa, Uganda3Active, not recruitingGilead SciencesMay 27, 20245,368
NCT04388904Acquired Immunodeficiency Syndrome · United States4CompletedThe Crofoot Research CenterApr 5, 202475
NCT04143594HIV-1-infection · United States, Dominican Republic, Puerto Rico2CompletedGilead SciencesOct 5, 2021183
NCT03960645HIV-1-infection · United States, Dominican Republic, Thailand1CompletedGilead SciencesJul 21, 202262
NCT03836729HIV Infections · United States1CompletedGlaxoSmithKlineMar 30, 201916
NCT03631732HIV-1 Infection · United States3CompletedGilead SciencesAug 12, 2019496
NCT03547908HIV-1/HBV Co-Infection · United States, China, Dominican Republic and more3CompletedGilead SciencesFeb 25, 2022244
NCT03405935HIV-1 Infection · Belgium, France, Italy and more3CompletedGilead SciencesNov 20, 201886
NCT03309566Healthy · Argentina4CompletedLaboratorio Elea PhoenixFeb 28, 201724
NCT03110380HIV-1-infection · United States, Austria, Canada and more3CompletedGilead SciencesDec 4, 2018567
NCT02842086Pre-Exposure Prophylaxis of HIV-1 Infection · United States, Austria, Canada and more3TerminatedGilead SciencesJan 31, 20195,399
NCT02707601Hepatitis C · United States, Puerto Rico3CompletedGilead SciencesSep 14, 2017150
NCT02652624HIV-1 Infection · United States, Dominican Republic, Puerto Rico and more3CompletedGilead SciencesOct 9, 2017472
NCT02616029HIV-1 Infection · United States, France, Germany and more3CompletedGilead SciencesOct 11, 201866
NCT02616783HIV-1 Infection · Belgium, France, Italy and more3CompletedGilead SciencesFeb 21, 2018167
NCT02605954HIV-1 Infection · United States, France, Germany and more3CompletedGilead SciencesJun 14, 2017275
NCT02607956HIV-1 Infection · United States, Australia, Belgium and more3CompletedGilead SciencesMay 12, 2017657
NCT02600819Kidney Failure, Chronic · United States, Austria, France and more3CompletedGilead SciencesSep 29, 201755
NCT02583464Acquired Immunodeficiency Syndrome · Argentina1CompletedLaboratorio Elea PhoenixOct 201424
NCT02469246HIV-1 Infection · United States, Belgium, Canada and more3CompletedGilead SciencesDec 11, 2017567
NCT02397694HIV-1 Infection · United States2CompletedGilead SciencesNov 30, 201598
NCT02276612HIV · United States, South Africa3CompletedGilead SciencesNov 10, 201660
NCT02121795HIV-1 Infection · United States, Belgium, Canada and more3CompletedGilead SciencesAug 12, 2015668
NCT02071082Coinfection · United States, Canada, Japan3CompletedGilead SciencesJan 23, 201579
NCT02016924Acquired Immunodeficiency Syndrome · United States, Argentina, South Africa and more3Active, not recruitingGilead SciencesJun 13, 2025133
NCT01967940HIV Infections · United States, Dominican Republic, Russian Federation and more3CompletedGilead SciencesMay 21, 201555
NCT01968551HIV Infections · United States, Canada3CompletedGilead SciencesJul 21, 2015158
NCT01854775Acquired Immunodeficiency Syndrome · United States, South Africa, Thailand and more3CompletedGilead SciencesMay 11, 2020129
NCT01818596HIV Infections · United States, Australia, Dominican Republic and more3CompletedGilead SciencesJul 31, 2014252
NCT01815736HIV Infections · United States, Australia, Austria and more3CompletedGilead SciencesMar 16, 20151,443
NCT01797445HIV Infections · United States, Canada, Dominican Republic and more3CompletedGilead SciencesSep 19, 2014872
NCT01780506HIV Infections · United States, Australia, Austria and more3CompletedGilead SciencesAug 26, 2014872
NCT00743340HIV-1 Infection · South Africa2CompletedGilead SciencesFeb 13, 201750
NCT00642291HIV Infections · Romania2CompletedGilead SciencesJul 200416
NCT00615745HIV Infections · United Kingdom4CompletedGilead SciencesNov 2010115
NCT00365612HIV Infections · United States, Puerto Rico4CompletedGilead SciencesOct 2007300
NCT00362687HIV Infections · Spain4CompletedGilead SciencesMay 200850
NCT00307489Hepatitis B, Chronic · United States, France, Germany and more2CompletedGilead SciencesJan 2008106
NCT00112047HIV Infections · United States3CompletedGilead SciencesFeb 2005517
NCT00106379HIV Infections · United States4CompletedGilead Sciences52
NCT00017992HIV Infections · United States, Argentina, Mexico and more2UNKNOWNTriangle Pharmaceuticals100
NCT00006208HIV Infections · United States, Argentina, Canada and more3UNKNOWNTriangle Pharmaceuticals
NCT00002362HIV Infections · United States3SuspendedTriangle Pharmaceuticals
NCT00002335HIV Infections · United States1CompletedGlaxoSmithKline18

How it is read

Names in the registry

  • “E/C/F/TAF”, 16 entries
  • “B/F/TAF”, 10 entries
  • “Emtricitabine”, 9 entries
  • “F/TAF”, 8 entries
  • “Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.